Results 71 to 80 of about 160,145 (308)

Simple change in logistic procedure improves response rate to QOL assessment: a report from the Japan Children’s Cancer Group

Journal of Patient-Reported Outcomes, 2020
Background Reducing non-completion of quality-of-life assessment in clinical trials is an important challenge in obtaining accurate data and unbiased interpretation of patients’ quality-of-life for each regimen.
Iori Sato, Takafumi Soejima, Yasushi Ishida, Miho Maeda, Katsuyoshi Koh, Kiyoko Kamibeppu   +5 more
doaj   +1 more source

WILMS' TUMOR GENE 1 (WT1) EXPRESSION IN CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA [PDF]

Zagazig University Medical Journal, 2014
Aim &Objectives: Wilms ٰ ٰ tumor 1 (Wt1) gene is over expressed in majorty of acute leukemia.The aim of this study is to evaluate(WT1) gene expression in children with acute lymphoblastic leukemia and to find out the relationship between it and other
Mohamed Badr, Tamer Hassan, Asmaa Esh, Wesam Mokhtar   +3 more
doaj   +1 more source

Acute Lymphoblastic Leukemia [PDF]

Journal of the National Comprehensive Cancer Network, 2012
The inaugural NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for acute lymphoblastic leukemia (ALL) were developed as a result of meetings convened by a multi-disciplinary panel of experts in 2011. These NCCN Guidelines provide recommendations on the diagnostic evaluation and workup for ALL, risk assessment, risk-stratified treatment ...
Joseph C, Alvarnas, Patrick A, Brown, Patricia, Aoun, Karen Kuhn, Ballen, Naresh, Bellam, William, Blum, Michael W, Boyer, Hetty E, Carraway, Peter F, Coccia, Steven E, Coutre, Jennifer, Cultrera, Lloyd E, Damon, Daniel J, DeAngelo, Dan, Douer, Haydar, Frangoul, Olga, Frankfurt, Salil, Goorha, Michael M, Millenson, Susan, O'Brien, Stephen H, Petersdorf, Arati V, Rao, Stephanie, Terezakis, Geoffrey, Uy, Meir, Wetzler, Andrew D, Zelenetz, Maoko, Naganuma, Kristina M, Gregory   +26 more
openaire   +2 more sources

A Novel NR3C1 Frameshift Variant Associated With Familial Glucocorticoid Resistance Syndrome: An Integrated Analysis of Steroid Profiling and Structural Modeling

American Journal of Medical Genetics Part A, EarlyView.
ABSTRACT Glucocorticoid resistance syndrome (GRS) is a rare hereditary disorder caused by pathogenic variants in NR3C1, characterized by marked phenotypic heterogeneity and frequent misdiagnosis as primary aldosteronism or subclinical Cushing's syndrome.
Sufang Yun, Zhifeng Zhu, Fengye Zhou, Ying Liu, Chunfang Liang, Haitao Ju, Lin Lu, Zhaoli Yan   +7 more
wiley   +1 more source

MicroRNA characterize genetic diversity and drug resistance in pediatric acute lymphoblastic leukemia

Haematologica, 2011
Background MicroRNA regulate the activity of protein-coding genes including those involved in hematopoietic cancers. The aim of the current study was to explore which microRNA are unique for seven different subtypes of pediatric acute lymphoblastic ...
Diana Schotte, Renée X. De Menezes, Farhad Akbari Moqadam, Leila Mohammadi Khankahdani, Ellen Lange-Turenhout, Caifu Chen, Rob Pieters, Monique L. Den Boer   +7 more
doaj   +1 more source

Acute lymphoblastic leukaemia [PDF]

The Lancet, 2013
Acute lymphoblastic leukaemia occurs in both children and adults but its incidence peaks between 2 and 5 years of age. Causation is multifactorial and exogenous or endogenous exposures, genetic susceptibility, and chance have roles. Survival in paediatric acute lymphoblastic leukaemia has improved to roughly 90% in trials with risk stratification by ...
Inaba, H., Greaves, M., Mullighan, C.G.
openaire   +3 more sources

Effect of developmental changes on pharmacokinetics of drugs used in the treatment of infant acute lymphoblastic leukaemia—A comprehensive review

British Journal of Clinical Pharmacology, EarlyView.
While the event‐free survival (EFS) of children treated for acute lymphoblastic leukaemia (ALL) has improved greatly in the last decades, the EFS for patients diagnosed with ALL before the age of one is still under 50%. This outcome further decreases when infants have a rearrangement in the gene encoding histone‐lysine N‐methyltransferase 2A (KMT2A ...
Tirsa de Kluis, Leiah J. Brigitha, Lidwien M. Hanff, Alwin D. R. Huitema, Inge M. van der Sluis, Meta H. M. Diekstra   +5 more
wiley   +1 more source

A case report of secondary B-cell acute lymphoblastic leukemia treated with a combination of FLT3 inhibitor and decitabine

Frontiers in Oncology
Secondary acute lymphoblastic leukemia (s-ALL) refers to acute lymphoblastic leukemia that occurs after a previous malignant tumor, including therapy-related acute lymphoblastic leukemia (t-ALL) and prior malignant tumor acute lymphoblastic leukemia (pm ...
Mengci Hu, Wenzhe Li, Pan Li, Jie Tan, Ya Wang, Ya Wang   +5 more
doaj   +1 more source

Prognostic relevance of RUNX1 mutations in T-cell acute lymphoblastic leukemia

Haematologica, 2011
The runt-related transcription factor 1, RUNX1, is crucial in the development of myeloid and lymphoid cell lineages and has been reported to be mutated in myeloid malignancies in approximately 30% of cases.
Vera Grossmann, Wolfgang Kern, Stefan Harbich, Tamara Alpermann, Sabine Jeromin, Susanne Schnittger, Claudia Haferlach, Torsten Haferlach, Alexander Kohlmann   +8 more
doaj   +1 more source

Efficacy, safety and cost‐effectiveness of CAR‐T therapy

British Journal of Clinical Pharmacology, EarlyView.
CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher, Amina Džidić‐Krivić, Emma Pinjic, Nejra Selak, Kanita Omerbasic, Alexandar Chupin, Andrej Belancic, Almir Fajkic   +7 more
wiley   +1 more source